trial · primary record
Teclistamab (IV)
Hematological Malignancies
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 302 |
| Primary completion | 2027-08-24 |
| Primary endpoint | Dose Limiting Toxicity (DLT) |
| Registry ID | NCT03145181 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:32.897Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03145181
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Teclistamab · compound